AquaBounty Technologies (NASDAQ:AQB) & Rani Therapeutics (NASDAQ:RANI) Head to Head Comparison

AquaBounty Technologies (NASDAQ:AQB) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AquaBounty Technologies and Rani Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1	0	0	0	1.00
Rani Therapeutics	1	0	4	1	2.83

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 988.31%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than AquaBounty Technologies.

Risk & Volatility

AquaBounty Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Earnings & Valuation

This table compares AquaBounty Technologies and Rani Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47 million	2.36	-$18.49 million	($0.82)	-1.38
Rani Therapeutics	$4.88 million	22.98	-$29.67 million	($0.27)	-2.98

AquaBounty Technologies has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares AquaBounty Technologies and Rani Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Rani Therapeutics beats AquaBounty Technologies on 10 of the 14 factors compared between the two stocks.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.